Association for Molecular Pathology                       
October 2009, Volume 15, Number 3                                   

Inside this Issue

Front Page
President's Message
Special Features
• AMP Advocacy
• AMP Test Directory
• JMD Report
• Web Editorial Board
• AMP 2009 Preliminary Program
• AMP 2009 Corporate Workshops

• Announcements
Committee Reports
• Clinical Practice Committee
• Membership & Professional   
  Development Committee
• Nominating Committee
• Professional Relations
• Program Committee
• Publications Committee
• Training & Education Committee
Subdivision Reports
• Genetics
• Hematopathology
• Infectious Diseases
• Solid Tumors
2009 AMP Officers and Appointees
AMP Advocacy

AMP Lobbies for Equitable Reimbursement

AMP has been vigorously advocating with members of Congress for several months to revise or reject legislation that would eliminate the 14-day waiting period for a wide spectrum of molecular tests - for laboratories that are independent of the hospital where the specimen was collected and not under any arrangements. This legislation first appeared as H.R. 1699 (Altmire, et al.) and S. 1220 (Specter & Wyden) and most recently as the Wyden #D10 Amendment to the Chairman’s Mark of the Senate Finance Committee’s health care reform bill. The proposed legislation provides an incentive for hospitals to cease performing these molecular tests in favor of outsourcing them to remove the cost from the DRG. The CAP, which has also been fighting the legislation, recently joined AMP to form a coalition that now is five organizations strong. Click here to read the most recent letter – sent to Sen. Max Baucus.

AMP Comments to the SACGHS on October 8
AMP took the opportunity to reiterate its position on gene patents, direct-to-consumer marketing of genetic testing, and genetic nondiscrimination to the Secretary’s Advisory Committee on Genetics, Health & Society (SACGHS) on October 8. Click here to read AMP’s comments.